LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its ...

Founder Vanessa Barboni Hallik celebrated Another Tomorrow's ready-to-wear Mirum pieces in conversation with animal rights ...

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

Ctexli significantly reduced levels of two atypical cholesterol metabolites usually elevated in patients with cerebrotendinous xanthomatosis (CTX) compared to the placebo. Common side effects of ...

(Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%. The company’s lead product is Livmarli (maralixibat ...

Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and set a price target of ...

Mirum Pharmaceuticals, Inc. is headquartered just outside of San Francisco in Foster City, CA. This commercial stage concern is focused in debilitating rare and orphan diseases within its pipeline ...

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative ...